Idt Australia Limited · ASX:IDT
Idt Australia — H1 2025 Earnings Presentation
18 slides from Idt Australia's earnings presentation, Feb 25, 2025
Slide 1: IDT Australia First Half FY2025 Results
IDT Australia FIRST HALF FY2025 RESULTS
Slide 2: Key Milestones in H1FY25
Key Milestones in H1FY25 Momentum Building On track to deliver a significantly improved FY25 result H1FY25 revenue jumped to $10.5M from $5.8M in pcp New contracts of $20M awarded in H1FY25, including $13M in Q4FY25 Significant and continuing shift to higher margin Advanced Therapies sales Sterile f
Slide 3: IDT Overview
IDT Overview IDT is an Australian pharmaceutical manufacturing company with extensive experience in the development and production of high potency and high containment pharmaceutical products for local and international clients 50 Years of Operational Excellence with 30 Novel Chemical Entities Pathw
Slide 4: Uplift in H1FY25 Sales Revenue
Uplift in H1FY25 Sales Revenue Best Result Since Start of Strategic Transformation Interim revenue jumped 83% pcp to $10.5M – its highest level since the transformation program over two years ago: ▪ Advanced Therapies pillar was the standout with a 1,116% pcp jump to $3.9M on margins that are typica
Slide 5: Track Record of Revenue Growth
Track Record of Revenue Growth Consistent Sales Growth - Expected to Continue Half-Year Sales Revenue Growth Millions $12 $10.5 $10 $7.8 $8 $5.7 $6 $4.5 $4 $2.4 $2 $0 H1FY23 H2FY23 H1FY24 H2FY24 H1FY25 Active Pharmaceutical Ingredients Speciality Oral Advanced Therapies Reimbursements/Other Income C
Slide 6: ~$20M New Contracts Awarded in H1FY25
~$20M New Contracts Awarded in H1FY25 Building Momentum into H2FY25 On track to post significantly stronger full year Breakdown of Contracts Won in H1FY25 results with IDT winning ~$20M in new contracts in Millions $14 H1FY25 $12 ▪ $12.9M new contracts won in Q2FY25, following $6.8M in Q1FY25 $10 $8
Slide 7: High Rates of Return Work
High Rates of Return Work Early Product Lifecycle & Follow-On Work Return customers ▪ Higher probability of winning follow-on work (lower risk for customers) New customer wins ▪ Usually at higher margins (due to efficiencies, etc.) ▪ Typically for drugs that are at early stage of their ▪ Usually for
Slide 8: Multiple Levers for Growth
Multiple Levers for Growth Drivers of Sustainable Growth to Improve Profitability 3 Improving sales mix & increasing repeat business 2 ▪ Changing sales mix to higher value ADC & mRNA drugs is providing Increasing utilisation rates added tailwind for margin expansion 1 ▪ All work won in H1FY25 were f
Slide 9: Core Pillars
Core Pillars Industry Leader with Integrated Offering Active Pharmaceutical Ingredients Advanced Therapies Specialty Orals 15% of H1FY25 Pillar Revenue ($1.0M) 56% of H1FY25 Pillar Revenue ($3.9M) 29% of H1FY25 Pillar Revenue ($2.0M) • IDT’s original business • High value platforms in emerging marke
Slide 10: H1FY25 Financial Results: Profit & Loss Statement
H1FY25 Financial Results Profit & Loss Statement Operating margins expected to grow ahead of revenue in the near-term through operating leverage, sales shift to high margin Advanced Therapies products and flow on from new recent API contract wins $’000 1H FY24 1H FY25 % Change Comments Active Pharma
Slide 11: H1FY25 Financial Results: Cash Flow Statement
H1FY25 Financial Results Cash Flow Statement Significantly improved cash generation expected in H2FY25 $’000 1H FY24 1H FY25 % Change Comments Receipts from customers (GST inclusive) $5,169 $8,806 70% Cash receipts generally lag revenue due to contract terms Significant investment in balance sheet (
Slide 12: H1FY25 Financial Results: Balance Sheet
H1FY25 Financial Results Balance Sheet Balance sheet reflects significant increase in sales and growth expectations based on existing contracted sales pipeline and prospects $’000 1H FY24 1H FY25 % Change Comments Cash and cash equivalents $504 $1,056 110% Trade and other receivables $5,373 $8,193 5
Slide 13: Corporate Information
Corporate Information IDT Australia (IDT.ASX) Key Metrics IDT Australia Share Price: 1 Year* Market capitalisation $45.1M Shares on issue (#) 429.8M FY24 revenue $14.1M H1FY25 revenue $10.5M Percentage of Total Shares on Issue (As at 12th February 2025) Top 20 Shareholders Others *As of 20 February
Slide 14: Directors & Management
Directors & Management Experienced Board and leadership team Mark Simari Geoffrey Sam, OAM Chair Non-Executive Director Mark Simari is an experienced and accomplished professional in the health industry and has over Geoffrey Sam brings with him a wealth of healthcare experience and accomplishments.
Slide 15: Outlook & Summary
Outlook & Summary Multiple Tailwinds & Growth Catalysts Positive outlook Revenue tailwinds On track to deliver improved full year result with $20M new Australia’s global attractiveness for clinical trials and growing contracts awarded in H1FY25 and $18m proposals submitted in demand for mRNA, ADC, e
Slide 16: Our Glossary
Our ADC Antibody Drug Conjugate GMP Good Manufacturing Practices API Active Pharmaceutical Ingredient mRNA Messenger Ribonucleic Acid Glossary CNS Central Nervous System ODC Office of Drug Control Acronym FDA U.S. Food and Drug Administration PMDA Pharmaceuticals and Medical Meanings Devices Agency
Slide 17: Disclaimer and Important Notice
Disclaimer and Important Notice This presentation has been prepared by IDT Australia Limited ACN 006 522 970 (Company). It contains general background information only which is current at the date of this presentation unless otherwise specified. It contains selected summary information and does not
Slide 18: IDT Australia
IDT Australia Investor & Media Enquiries: Brendon Lau e: brendon@vantagepointpartners.com.au m: 0409 341 613